MAP4K

HPK1-IN-31 is a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor, exhibiting an IC50 value of 0.8 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool in cancer research. Its ability to modulate immune responses further enhances its potential applications in immunological studies.

HPK1 antagonist-1 (I-792) is a selective antagonist of HPK1, a key regulator involved in immune signaling pathways. This compound exhibits significant biological activity by inhibiting HPK1-mediated signaling, making it a valuable tool for investigating its role in cancer progression and immune disorders. Researchers can utilize HPK1 antagonist-1 to explore therapeutic strategies targeting HPK1 in various disease models.

HPK1-IN-21 is a potent inhibitor of HPK1 kinase, exhibiting a Ki value of 0.8 nM. This compound demonstrates significant biological activity in modulating immune responses through inhibition of T-cell signaling pathways. HPK1-IN-21 is of particular interest for research applications in cancer immunotherapy and the study of autoimmune diseases.

HDM2004 is a selective inhibitor of HPK1, demonstrating potent activity with an IC50 of 1.89 nM. This compound is orally bioavailable and effectively penetrates the blood-brain barrier, exhibiting notable anticancer activity against colon cancer. Additionally, HDM2004 shows synergistic effects when used in combination with anti-PD-L1 in syngeneic mouse models, making it a valuable tool for research into colon cancer therapies.

HMC-B17 is a selective inhibitor of HPK1, exhibiting an IC50 of 1.39 nM. It enhances the secretion of IL-2 in Jurkat cells, with an EC50 of 11.56 nM, thereby potentiating the efficacy of anti-PD-L1 therapies. This compound is valuable for research into cancer mechanisms and immunotherapy strategies.

HPK1-IN-36 is a potent inhibitor of HPK1, exhibiting an IC50 value of 0.5 nM. This compound selectively targets the HPK1 signaling pathway, which plays a crucial role in T cell activation and immune response regulation. HPK1-IN-36 is valuable for research applications aimed at understanding immune modulation and investigating potential therapies for autoimmune diseases and immune-related disorders.

HPK1-IN-41 is a potent inhibitor of the HPK1 protein, exhibiting an IC50 value of 0.21 μM. This compound is instrumental in research focused on diseases linked to HPK1 activity, enabling studies on its role in various cellular processes and potential therapeutic interventions. Its utility in modulating HPK1 makes it a valuable tool for exploring targeted treatments in related pathologies.

HPK1 ligand 6 is an effective ligand for Hematopoietic Progenitor Kinase 1 (HPK1), targeting its regulatory pathways. This compound plays a crucial role in cellular signaling and immune responses, making it a valuable tool for studying the functions of HPK1. Additionally, HPK1 ligand 6 can be utilized to synthesize PROTAC HPK1 Degrader-6, facilitating research into targeted protein degradation and therapeutic applications in various diseases.

HPK1-IN-27 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase within the MAP4K family. This compound modulates critical signaling pathways involved in cell proliferation and survival, making it a valuable tool for cancer research. Its ability to inhibit HPK1 activity contributes to investigations into the mechanistic roles of this kinase in tumorigenesis and potential therapeutic interventions.

HPK1-IN-28 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), which functions as a negative regulator in the activation of dendritic cells, T cells, and B cells. This compound enhances anti-tumor immunity, making it a valuable tool for research in immune-related diseases, particularly in tumor immunology. HPK1-IN-28 offers significant potential for investigating therapeutic strategies aimed at modulating immune responses.

HPK1-IN-35 is a potent and selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM. This compound effectively reduces the phosphorylation of SLP76 while promoting the secretion of interleukin-2 (IL-2). HPK1-IN-35 is particularly valuable for research in T cell activation and immune response modulation.

HPK1-IN-49 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 value exceeding 100 nM. This compound is utilized in research to study the role of HPK1 in various cellular processes, including immune responses and signal transduction pathways. Its inhibition can provide insights into therapeutic strategies targeting HPK1-related diseases.

HPK1-IN-29 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a key negative regulator in the activation of dendritic cells, T cells, and B cells. By inhibiting HPK1, this compound enhances anti-tumor immune responses. HPK1-IN-29 is valuable for research into immune-related diseases, particularly in the context of cancer immunotherapy and tumor microenvironment modulation.

HPK1-IN-52 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 value of 10.4 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for studying the role of HPK1 in cancer biology. HPK1-IN-52 can be utilized in various research applications aimed at elucidating therapeutic strategies targeting HPK1-mediated pathways.

HPK1-IN-9 is a potent inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), a serine/threonine protein kinase associated with the MAP4K family of Ste-20-related protein kinases. This compound demonstrates significant biological activity in modulating HPK1 signaling pathways, making it a valuable tool for research into HPK1-related diseases. Researchers investigating the roles of HPK1 in various cellular processes may find HPK1-IN-9 particularly useful for elucidating its potential therapeutic implications.

HPK1-IN-38 is a selective inhibitor of MAP4K1, also known as HPK1. This compound exhibits potent inhibition of HPK1's kinase activity, making it a valuable tool for studying HPK1-related biological processes. Its application is particularly relevant in research focused on immune response modulation and cancer biology, where HPK1 plays a critical role.

HPK1-IN-20 is a specific inhibitor of hematopoietic progenitor kinase 1 (HPK1), which plays a critical role in immune signaling pathways. This compound demonstrates strong inhibition of HPK1 activity, which may enhance T cell activation and proliferation. It is suitable for research applications focused on immunological studies and potential therapeutic development for immune-related disorders.

HPK1-IN-37 is a selective inhibitor of MAP4K1/HPK1, demonstrating an IC50 of 3.7 nM. Its potent inhibitory activity makes it a valuable tool for investigating HPK1-related disorders, including various cancer types. Researchers can utilize HPK1-IN-37 to elucidate the role of HPK1 in signal transduction pathways and therapeutic interventions.

BAY-405 is a potent MAP4K1 inhibitor that demonstrates nanomolar activity in both biochemical and cellular assays. Its effective inhibition of MAP4K1 has significant implications for research into pathways regulated by this kinase, making it a valuable tool for studying cellular processes such as proliferation, differentiation, and stress response. Additionally, BAY-405 is capable of achieving in vivo exposure following oral administration, enhancing its utility in preclinical studies.

HPK1-IN-30 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase belonging to the MAP4K family. This compound demonstrates significant biological activity by modulating HPK1 signaling pathways, which are implicated in various cancers. HPK1-IN-30 is valuable for research applications focused on cancer biology and therapeutic development targeting the HPK1 pathway.

HPK1-IN-33 is a potent inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), exhibiting a Ki value of 1.7 nM. This compound effectively inhibits IL-2 production, demonstrating an EC50 of 286 nM in Jurkat wild-type cells and greater than 10,000 nM in Jurkat HPK1 knockout cells. HPK1-IN-33 is applicable in studies focused on immune response modulation and therapeutic interventions targeting T cell activation.

HPK1-IN-55 is a highly selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), exhibiting an IC50 of less than 0.51 nM. This compound demonstrates significant selectivity for HPK1, with over 637-fold selectivity against GCK-like kinases and over 1022-fold against LCK. HPK1-IN-55 has been shown to possess anticancer properties, making it a valuable tool for research into cancer therapies and the regulation of hematopoietic cells.

HPK1-IN-60 is an inhibitor of the HPK1 protein kinase, which plays a critical role in regulating T cell activation. This compound exhibits significant potential in antitumor immunotherapy research by modulating immune responses. It is a valuable tool for studying the mechanisms of immune regulation and exploring therapeutic strategies in cancer treatment.

HPK1-IN-42 is a potent inhibitor of HPK1, exhibiting an IC50 value of 0.24 nM. This compound is valuable for studying the regulation of T cell receptor signaling and its implications in immune responses. Its use in research can advance understanding of HPK1's role in cellular processes and therapeutic strategies for immune-related diseases.

HPK1-IN-54 is a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), significantly enhancing T cell activation and proliferation. With an IC50 value of 2.67 nM, it demonstrates over 100-fold selectivity against the MAP4K family and over 300-fold selectivity for other kinases. This compound exhibits potent antitumor effects, evidenced by strong efficacy in a CT26 murine colon cancer model and the ability to synergize with anti-PD-1 therapies. HPK1-IN-54 offers a valuable tool for research in immunotherapy applications.

HPK1-IN-24 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1) with a Ki value of 100 nM. This compound is designed for applications in cancer research, where targeting HPK1 may enhance the understanding of tumorigenesis and cellular signaling pathways. Its inhibition of HPK1 allows for the exploration of novel therapeutic strategies in oncology.

PF-06260933 hydrochloride is a selective inhibitor of the MAP4K4 kinase, demonstrating an IC50 of 3.7 nM in enzymatic assays and 160 nM in cellular studies. This compound is orally active and is utilized in research focused on understanding the signaling pathways associated with MAP4K4. Its inhibition of MAP4K4 positions it as a valuable tool for investigating therapeutic strategies in diseases linked to aberrant MAP4K4 activity.

HPK1-IN-46 is a selective inhibitor of HPK1, demonstrating an IC50 value of 1.1 nM. This compound effectively inhibits SLP76 phosphorylation mediated by HPK1, resulting in the reversal of T-cell inhibition and an enhancement of anti-tumor immunity. HPK1-IN-46 is valuable in immunotherapy research for tumors, particularly in exploring T-cell regulatory mechanisms and tumor microenvironment interactions.

HPK1-IN-25 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an enzymatic activity IC50 of 129 nM. This compound is valuable for cancer research, as HPK1 plays a significant role in regulating cell proliferation and apoptosis. Researchers may utilize HPK1-IN-25 to investigate its effects on tumor growth and lymphocyte signaling pathways.